New-onset migraine with aura after transcatheter closure of atrial septal defect

Yuji Kato · Daisuke Furuya · Hirotaka Ishido · Toshiki Kobayashi · Norio Tanahashi

Received: 27 February 2012/Accepted: 4 May 2012/Published online: 24 May 2012
© The Author(s) 2012. This article is published with open access at Springerlink.com

Abstract Transcatheter closure of atrial septal defect (ASD) is associated with a high success rate and becomes an accepted alternative to surgical treatment. We describe here a case of a 35-year-old woman who presented with migraine attacks with aura after transcatheter closure of ASD with an Amplatzer septal occluder device. We postulate that any of the following may have been responsible for her condition: platelet activation on the surface of the device, nickel allergy, or the release of the atrial natriuretic peptide associated with the stretch of the atrial septum caused by the device. This case demonstrates that de novo migraine can occur after transcatheter closure of ASD and should be recognized as a potential complication.

Keywords Migraine · Atrial septal defect · Transcatheter closure · Amplatzer septal occluder

Case report

A 35-year-old female with a negative family history and personal history of headaches or other illness of interest was seen to have abnormal ECG findings (right axis deviation and right ventricular hypertrophy) during the course of a routine medical checkup. She was asymptomatic and was referred to our institution for further cardiac evaluation. Following transthoracic echocardiography, she was diagnosed with an ostium secundum ASD with significant left-to-right shunting (approximate $Q_p/Q_s$ ratio of 2:1). It was seen to measure 12 mm in stop-flow diameter by transesophageal echocardiography. Transcatheter closure of the defect was performed with an Amplatzer septal occluder device (15 mm). Treatment with aspirin (200 mg) was started 24 h before the procedure. The next morning, the patient began to notice blurry vision in the left eye for 20 min several times a day. Two days later, the patient developed scintillating scotoma, which gradually expanded over 5–20 min, followed by a pulsating headache in the
bilateral forehead accompanied by photophobia, which improved spontaneously after ~4 h.

Subsequently, she suffered similar headaches twice a week. The intensity and duration of headache increased and were made worse by routine physical activity and nausea. As a result of these symptoms, cerebral magnetic resonance imaging was performed, the result of which was normal. She fulfilled International Headache Society criteria for typical aura with migraine headache (ICHD-II code 1.2.1). Numerous transthoracic echocardiography failed to reveal any images suggestive of thrombus on the device surface or in the cardiac cavities (Fig. 1), though post-operative minor leakage left-to-right shunting through the device was detected. A transthoracic echocardiography performed 2 months after ASD closure did not reveal any residual shunt. The minor leakage may cause platelet activation. Unfortunately, we did not perform transcranial Doppler. We switched from aspirin to sarpogrelate hydrochloride (300 mg/day) and then to clopidogrel (75 mg/day). Although clopidogrel was continued for 3 months, the patient had no response with resolution of her headaches. During some MHA, the patient took eletriptan as soon as she noticed the headache, and the headache was improved within the first hour. Prophylactic treatment with lomerizine, a calcium channel blocker, was initiated 4 weeks after the onset of migraine headache and continued for 6 months. The frequency of headache attacks gradually decreased and disappeared 9 months after the onset. After a 2-year follow-up, she suffered periodic auras without headache for approximately once a month under no medication.

Discussion

The possibility of ASD being a predictive risk factor for migraine is less evident than in the case of PFO, although the prevalence of migraine in patients with ASD seemed to be increased compared to the general population [7]. Nevertheless, cases of de novo migraine or exacerbated migraine with aura in prior migraine sufferers have been described following percutaneous closure of some ASD [3–6], something that does not appear to hold true in the case of similar treatment procedures for PFO.

De novo development of migraine, mostly with aura, has been reported in single or case series. In a retrospective study using questionnaires, Mortelmans et al. [3] reported an incidence of 19 % of new-onset MHA after transcatheter ASD closure. Similarly, Voet et al. [5] reported an incidence of 12 % that disappeared at long-term follow-up. Sharifi et al. [4] reported response of five post-ASD closure migraineurs to a loading dose of 300 mg clopidogrel. In a retrospective analysis, Rodés-Cabau et al. [6] found de novo migraine in 12 % of patients after ASD closure compared with 0 % after PFO closure. The first migraine episode occurred mostly within 2 weeks after the closing procedure and persisted in 2/3 of the cases for more than 2 years. However, in a prospective study, Riederer et al. [7] did not observe de novo migraine in any patients.

The mechanisms that account for the occurrence of new-onset MHA after ASD closure remain unclear. Platelet activation on the surface of the device has ever been proposed as a mechanism of migraine in these cases. Recently, Nozari et al. [8] demonstrated that microemboli triggered cortical spreading depression without causing microinfarction in a mouse model. Even if there is no brain ischemic defect, microembolic theory cannot necessarily be denied. Also, nickel allergy might be responsible for migraine occurrence or aggravation in these patients [9]. However, neo-endothelialization of an ASD device usually occurs within the first 3 months after device implantation [10], leading to the expectation of the disappearance of migraine attacks in most patients after this period of time, if transient platelet activation and/or nickel release were the triggers for migraine in these cases. As MHA’s in the present case persisted for over 3 months and both clopidogrel and sarpogrelate hydrochloride were not effective, our data do not support these hypotheses. As another hypothesis, the stretch of the atrial septum caused by the device itself might induce the release of the atrial natriuretic peptide (ANP) from the atrial myocytes, a vasoactive antagonist of vasopressin that has been proposed as a possible link between ASD closure and migraine aggravation [5, 6].

A possible mechanism, therefore, of de novo migraine attacks after ASD in our patient could be associated with
elevated or changed level of ANP as a consequence of intra-atrial pressure imbalance after closure. Further mechanistic studies with long-term ANP measurement are needed to clarify the pathophysiologic basis for the occurrence of migraine attacks after ASD closure. We are planning a prospective study about the influence of ASD closure on migraine.

**Conflict of interest**  The authors report that they have no conflicts of interest.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

**References**

1. Schwerzmann M, Nedeltchev K, Meier B (2007) Patent foramen ovale closure: a new therapy for migraine. Catheter Cardiovasc Interv 69:277–284
2. Dowson A, Mullen MJ, Peatfield R, Muir K, Khan AA, Wells C, Lipscombe SL, Rees T, De Giovanni JV, Morrison WL, Hildick-Smith D, Elrington G, Hillis WS, Malik IS, Rickards A (2008) Migraine Intervention With STARFlex Technology (MIST) trial: a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation 117:1397–1404
3. Mortelmans K, Post M, Thijs V, Herroelen L, Budts W (2005) The influence of percutaneous atrial septal defect closure on the occurrence of migraine. Eur Heart J 26:1533–1537
4. Sharifi M, Dehghani M, Mehdipour M, Al-Bustami O, Emrani F, Burks J (2005) Intense migraines secondary to percutaneous closure of atrial septal defects. J Interv Cardiol 18:181–183
5. Voet A, Luermans JG, Thijs V, Herroelen L, Post MC, Troost E, Budts W (2008) New-onset and persistent migraine early after percutaneous atrial septal defect closure disappear at follow-up. Acta Clin Belg 63:262–268
6. Rodés-Cabau J, Mineau S, Marrero A, Houde C, Mackey A, Côté JM, Chetaille P, Delisle G, Bertrand OF, Rivest D (2008) Incidence, timing, and predictive factors of new-onset migraine headache attack after transcatheter closure of atrial septal defect or patent foramen ovale. Am J Cardiol 101:688–692
7. Riederer F, Baumgartner H, Sándor PS, Wessely P, Wöber C (2011) Headache in 25 consecutive patients with atrial septal defects before and after percutaneous closure—a prospective case series. Headache 51:1297–1304
8. Nozari A, Dilekoz E, Sukhotinsky I, Stein T, Eikermann-Haerter K, Liu C, Wang Y, Frosch MP, Waebre C, Ayata C, Moskowitz MA (2010) Microemboli may link spreading depression, migraine aura, and patent foramen ovale. Ann Neurol 67:221–229
9. Wertman B, Azarbal B, Riedl M, Tobis J (2006) Adverse events associated with nickel allergy in patients undergoing percutaneous atrial septal defect or patent foramen ovale closure. J Am Coll Cardiol 47:1226–1227
10. Sharafuddin MJ, Gu X, Titus JL, Umess M, Cervera-Ceballos JJ, Amplatz K (1997) Transvenous closure of secundum atrial septal defects: preliminary results with a new self-expanding nitinol prosthesis in a swine model. Circulation 95:2162–2168